fda compounding semaglutide crackdown november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Intensifies Crackdown on GLP-1
Description
Dunham can only eat about a third or half the amount she used to before feeling full, she said

Although these mechanisms have been exploited to facilitate weight loss, these medications have also been indicated for patients with cardiovascular or renal diseases, all of which have caused a recent drastic rise in prescribing GLP-1 RAs

When medications are tailored to individual characteristics, whether its the form of the drug or the ingredients, it can lead to better health outcomes

Brubaker et al

Without adequate protein intake and proper metabolic support, a significant portion can come from lean muscle mass
